TREA

88083193 - SYNTHORX

Follow

Information

  • Trademark
  • 88083193
  • Serial Number
    88083193
  • Filing Date
    August 17, 2018
    6 years ago
  • Transaction Date
    February 07, 2024
    a year ago
  • Status Date
    May 16, 2022
    3 years ago
  • Published for Opposition Date
    February 12, 2019
    6 years ago
  • Location Date
    August 24, 2021
    3 years ago
  • Status Code
    606
  • Current Location
    INTENT TO USE SECTION
    Employee Name
    BEGGS, MONICA L
  • Attorney Docket Number
    SYNX 2001820
    Attorney Name
    Karen Lim
    Law Office Assigned Location Code
    L50
  • Owners
Information
Mark Drawing Code
4000
Mark Identification
SYNTHORX
Case File Statements
  • GS0051: Protein therapeutics expressed, prepared or manufactured using a semi-synthetic organism, namely, pharmaceutical preparations for use in immunology, oncology including immuno-oncology, cardiovascular and metabolic diseases, and infectious diseases; protein therapeutics expressed, prepared or manufactured using a semi-synthetic organism, namely, proteins designed to deliver highly targeted therapeutic modulation for patients suffering from a variety of diseases, including cancer, autoimmune and inflammatory diseases including transplantation and delayed-type hypersensitivity, respiratory diseases, gastrointestinal diseases, cardiovascular and metabolic diseases, pathogen infections, musculoskeletal diseases, ophthalmologic and dermatologic diseases, genitourinary diseases, degenerative diseases, and orphan diseases; protein therapeutics namely, pharmaceutical preparations for use in immunology including rheumatology, oncology including immuno-oncology, pulmonology, gastroenterology, endocrinology, dermatology, urology, gynecology including fertility, infectiology including virology, ophthalmology, hepatology, neurology, and geriatrics; protein therapeutics, namely, proteins designed to deliver highly targeted therapeutic modulation for patients suffering from a variety of diseases, including cancer and autoimmune disorders, cytokines, interferons, tumor cell targeting and cytolytic agents, tolerogenic and antiallergic factors, growth and differentiation factors, hormones, replacement enzymes, coagulation factors, lipid binding proteins, protein factors for manufacturing of adoptive cell therapy products, anti-infectives, pain killers, and tissue repair factors; non-natural protein modifications for use in connection with a variety of therapeutic areas, namely, protein arrays for medical diagnosis purposes; pharmaceutical preparations, namely, synthetic proteins for use in immunology including rheumatology, oncology including immuno-oncology, pulmonology, gastroenterology, endocrinology, dermatology, urology, gynecology including fertility, infectiology including virology, ophthalmology, hepatology, neurology, and geriatrics
  • GS0421: Medical research; scientific research in the field of DNA; pharmaceutical research and development; laboratory research services in the field of pharmaceuticals; pharmaceutical research in the field of protein therapeutics; pharmaceutical research in the fields of immunology including rheumatology, oncology including immuno-oncology, pulmonology, gastroenterology, endocrinology, dermatology, urology, gynecology including fertility, infectiology including virology, ophthalmology, hepatology, neurology, geriatrics, genetics and phenomics, pathology and forensics, proteomics, and veterinary medicine and diagnostics; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; pharmaceutical research using a semi-synthetic organism for use in drug development; pharmaceutical research, namely, research relating to synthetic proteins incorporating one or more non-natural amino acids for improving pharmacological properties; pharmaceutical research, namely, research relating to synthetic proteins for use in connection with a wide variety of therapeutic agents
Case File Event Statements
  • 5/16/2022 - 3 years ago
    43 - ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED Type: MAB6
  • 5/16/2022 - 3 years ago
    42 - ABANDONMENT - NO USE STATEMENT FILED Type: ABN6
  • 8/25/2021 - 3 years ago
    41 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Type: EXRA
  • 8/24/2021 - 3 years ago
    40 - SOU EXTENSION 5 GRANTED Type: EX5G
  • 8/19/2021 - 3 years ago
    39 - SOU EXTENSION 5 FILED Type: EXT5
  • 8/24/2021 - 3 years ago
    38 - CASE ASSIGNED TO INTENT TO USE PARALEGAL Type: AITU
  • 8/19/2021 - 3 years ago
    37 - SOU TEAS EXTENSION RECEIVED Type: EEXT
  • 2/16/2021 - 4 years ago
    36 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Type: EXRA
  • 2/12/2021 - 4 years ago
    35 - SOU EXTENSION 4 GRANTED Type: EX4G
  • 2/12/2021 - 4 years ago
    34 - SOU EXTENSION 4 FILED Type: EXT4
  • 2/12/2021 - 4 years ago
    33 - SOU TEAS EXTENSION RECEIVED Type: EEXT
  • 9/11/2020 - 4 years ago
    32 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Type: EXRA
  • 9/9/2020 - 4 years ago
    31 - SOU EXTENSION 3 GRANTED Type: EX3G
  • 9/9/2020 - 4 years ago
    30 - SOU EXTENSION 3 FILED Type: EXT3
  • 9/9/2020 - 4 years ago
    29 - SOU TEAS EXTENSION RECEIVED Type: EEXT
  • 4/1/2020 - 5 years ago
    28 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Type: EXRA
  • 3/30/2020 - 5 years ago
    27 - SOU EXTENSION 2 GRANTED Type: EX2G
  • 3/30/2020 - 5 years ago
    26 - SOU EXTENSION 2 FILED Type: EXT2
  • 3/30/2020 - 5 years ago
    25 - SOU TEAS EXTENSION RECEIVED Type: EEXT
  • 2/10/2020 - 5 years ago
    24 - APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Type: CHAN
  • 2/10/2020 - 5 years ago
    23 - TEAS CHANGE OF OWNER ADDRESS RECEIVED Type: COAR
  • 2/7/2020 - 5 years ago
    22 - ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Type: ARAA
  • 2/7/2020 - 5 years ago
    21 - TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Type: REAP
  • 10/1/2019 - 5 years ago
    20 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Type: EXRA
  • 9/27/2019 - 5 years ago
    19 - SOU EXTENSION 1 GRANTED Type: EX1G
  • 9/27/2019 - 5 years ago
    18 - SOU EXTENSION 1 FILED Type: EXT1
  • 9/27/2019 - 5 years ago
    17 - SOU TEAS EXTENSION RECEIVED Type: EEXT
  • 4/9/2019 - 6 years ago
    16 - NOA E-MAILED - SOU REQUIRED FROM APPLICANT Type: NOAM
  • 2/12/2019 - 6 years ago
    15 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 2/12/2019 - 6 years ago
    14 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 1/23/2019 - 6 years ago
    13 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 1/7/2019 - 6 years ago
    12 - ASSIGNED TO LIE Type: ALIE
  • 12/13/2018 - 6 years ago
    11 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 12/13/2018 - 6 years ago
    10 - EXAMINER'S AMENDMENT ENTERED Type: XAEC
  • 12/13/2018 - 6 years ago
    9 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN
  • 12/13/2018 - 6 years ago
    8 - EXAMINERS AMENDMENT E-MAILED Type: GNEA
  • 12/13/2018 - 6 years ago
    7 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA
  • 12/13/2018 - 6 years ago
    6 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 12/13/2018 - 6 years ago
    5 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 12/13/2018 - 6 years ago
    4 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 12/4/2018 - 6 years ago
    3 - ASSIGNED TO EXAMINER Type: DOCK
  • 8/27/2018 - 6 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 8/21/2018 - 6 years ago
    1 - NEW APPLICATION ENTERED Type: NWAP